RATIONALE: A growing number of controlled clinical trials suggest that different second-generation antidepressants (SGA) may be effective in the treatment of social anxiety disorder (SAD). OBJECTIVES: The aim of the present study is to evaluate the effectiveness of SGA in SAD and to investigate possible differences in their efficacy. METHODS: We performed a systematic review and meta-analysis of all double-blind, randomized, controlled clinical trials involving second-generation antidepressants in adult patients with SAD published on PubMed/MEDLINE, PsycINFO, and Current Controlled Trials databases until July 2009. Our analyses were based on changes in Liebowitz Social Anxiety Scale (LSAS), Clinical Global Impression (CGI), and standardized mean difference (SMD). RESULTS: Twenty-seven controlled clinical trials, comprising ten different SGA, were selected. When comparing the reduction of LSAS scores, the group receiving active drugs showed a significantly greater reduction compared to those observed in the placebo group [pooled weighted mean -11.9 (IC 95% -14.5 to -9.4)]. The combined relative risk (RR) for the different drugs revealed a 62% increase in treatment response (final CGI ≤2) for those using SGAs, compared to those receiving placebo [RR 1.62 (95% CI 1.44-1.81)]. The combined SMD for the SGAs was -0.43 (IC 95% -0.49 to -0.37). CONCLUSION: Second-generation antidepressants are efficacious treatment for patients with SAD. However, our results do not suggest differences of efficacy among different drugs.
RATIONALE: A growing number of controlled clinical trials suggest that different second-generation antidepressants (SGA) may be effective in the treatment of social anxiety disorder (SAD). OBJECTIVES: The aim of the present study is to evaluate the effectiveness of SGA in SAD and to investigate possible differences in their efficacy. METHODS: We performed a systematic review and meta-analysis of all double-blind, randomized, controlled clinical trials involving second-generation antidepressants in adult patients with SAD published on PubMed/MEDLINE, PsycINFO, and Current Controlled Trials databases until July 2009. Our analyses were based on changes in Liebowitz Social Anxiety Scale (LSAS), Clinical Global Impression (CGI), and standardized mean difference (SMD). RESULTS: Twenty-seven controlled clinical trials, comprising ten different SGA, were selected. When comparing the reduction of LSAS scores, the group receiving active drugs showed a significantly greater reduction compared to those observed in the placebo group [pooled weighted mean -11.9 (IC 95% -14.5 to -9.4)]. The combined relative risk (RR) for the different drugs revealed a 62% increase in treatment response (final CGI ≤2) for those using SGAs, compared to those receiving placebo [RR 1.62 (95% CI 1.44-1.81)]. The combined SMD for the SGAs was -0.43 (IC 95% -0.49 to -0.37). CONCLUSION: Second-generation antidepressants are efficacious treatment for patients with SAD. However, our results do not suggest differences of efficacy among different drugs.
Authors: Richard A Hansen; Bradley N Gaynes; Gerald Gartlehner; Charity G Moore; Ruchi Tiwari; Kathleen N Lohr Journal: Int Clin Psychopharmacol Date: 2008-05 Impact factor: 1.659
Authors: Dawson W Hedges; Bruce L Brown; David A Shwalb; Kirk Godfrey; A Manja Larcher Journal: J Psychopharmacol Date: 2006-05-19 Impact factor: 4.153
Authors: Jonathan R T Davidson; Edna B Foa; Jonathan D Huppert; Francis J Keefe; Martin E Franklin; Jill S Compton; Ning Zhao; Kathryn M Connor; Thomas R Lynch; Kishore M Gadde Journal: Arch Gen Psychiatry Date: 2004-10
Authors: Taryn Williams; Coenraad J Hattingh; Catherine M Kariuki; Sean A Tromp; Anton J van Balkom; Jonathan C Ipser; Dan J Stein Journal: Cochrane Database Syst Rev Date: 2017-10-19
Authors: William V Bobo; Jyotishman Pathak; Hilal Maradit Kremers; Barbara P Yawn; Scott M Brue; Cynthia J Stoppel; Paul E Croarkin; Jennifer St Sauver; Mark A Frye; Walter A Rocca Journal: J Am Med Inform Assoc Date: 2014-04-29 Impact factor: 4.497
Authors: Wejdan M Al-Johani; Nouf A AlShamlan; Naheel A AlAmer; Rammas A Shawkhan; Ali H Almayyad; Layla M Alghamdi; Hatem A Alqahtani; Malak A Al-Shammari; Danya Mohammed Khalid Gari; Reem S AlOmar Journal: BMC Psychiatry Date: 2022-07-27 Impact factor: 4.144